Mubadala Investment Co PJSC
Institutional investor · Portfolio as of Q3 2024
Top Holdings14 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
GLOBALFOUNDRIES INC | 450.4M | $18.1B | 96.3% | $60.60 | -32.43% | 4 qtrssince 2023-Q4 | Decreased 0 |
ARM Holdings PLC Sponsored ADR | 1.5M | $214.8M | 1.1% | $75.14 | +93.75% | 4 qtrssince 2023-Q4 | Unchanged 0 |
CERTARA INC | 9.6M | $112.6M | 0.6% | $17.59 | -54.52% | 4 qtrssince 2023-Q4 | Unchanged 0 |
RECURSION PHARMACEUTICALS IN | 13M | $85.6M | 0.5% | $9.86 | -29.21% | 4 qtrssince 2023-Q4 | Unchanged 0 |
ARIS MINING CORPORATION | 15.8M | $72.5M | 0.4% | $3.76 | +24.73% | 2 qtrssince 2024-Q2 | Unchanged 0 |
NEXTDECADE CORP | 14.2M | $66.9M | 0.4% | $4.77 | +0.63% | 4 qtrssince 2023-Q4 | Unchanged 0 |
ENDEAVOR GROUP HLDGS INC | 2.2M | $63.8M | 0.3% | — | — | 4 qtrssince 2023-Q4 | Unchanged 0 |
TURING HOLDING CORP | 7.8M | $34.4M | 0.2% | — | — | 4 qtrssince 2023-Q4 | Unchanged 0 |
COUPANG INC | 1M | $24.6M | 0.1% | $16.19 | -0.43% | 4 qtrssince 2023-Q4 | Decreased 0 |
EVOTEC AG | 4.6M | $16.8M | 0.1% | $11.73 | -69.57% | 4 qtrssince 2023-Q4 | Unchanged 0 |
NEBIUS GROUP NV | 539,751 | $10.2M | 0.1% | — | — | 4 qtrssince 2023-Q4 | Unchanged 0 |
OUTSET MED INC | 1.4M | $975,287 | 0.0% | — | — | — | — |
ENVIVA INC | 472,529 | $191,280 | 0.0% | — | — | 4 qtrssince 2023-Q4 | Unchanged 0 |
| 2.2M | $110,999 | 0.0% | — | — | 4 qtrssince 2023-Q4 | Unchanged 0 |
Mubadala Investment Co PJSC manages $18.8B across 14 positions as of Q3 2024. Top holdings: GFS (96.3%), ARM (1.1%), CERT (0.6%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2.5/5.0.
Exited 5, trimmed 2. No standout high-conviction moves this quarter. Portfolio: $18.8B across 14 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer